Testing efficacy of Lead Components

The Replication Combing Assay

The Replication Combing Assay is a unique approach that is well suited to test the efficacy of lead compounds by studying DNA replication in proliferating cancer cells and comparing the modes of action of drug candidates.

Dynamic changes to the genome structure and to the DNA replication program represent a major source of genomic instability in precancerous lesions and play a central role in the cancer process.

There are currently only a few genomics-based tools for drug validation and none of them target the kinetics of DNA replication. We have developed the Replication Combing Assay to monitor the kinetics of DNA replication during cell division in normal and pathological cells.

By using the test to evaluate the efficacy of anti-cancer molecules and to detect genomic instability, pharmaceutical companies will have access to a novel, high-performance approach for the development of new clinically active drugs.

We aim to help the pharmaceutical industry improve its R&D productivity by identifying the best leads from hundreds of compounds early in drug discovery. The Replication Combing Assay is available as a service (contact Genomic Vision.)

The Replication Combing Assay has the potential to be faster and more precise than traditional non-genomics based approaches.

“Genomic Vision is proposing something new, not like transcriptional profiling. This assay is highly precise, highly accurate and it is possible to do dedicated experiments.”
Jean-François Deleuze, Scientific Director at the Evry Genetics Center, sanofi aventis

Genomic Vision